DK2379581T3 - Fremgangsmåde til identifikation af hetero-multimerisk modificerede ubiquitinproteiner med evne til binding til ligander - Google Patents
Fremgangsmåde til identifikation af hetero-multimerisk modificerede ubiquitinproteiner med evne til binding til liganderInfo
- Publication number
- DK2379581T3 DK2379581T3 DK10787815.9T DK10787815T DK2379581T3 DK 2379581 T3 DK2379581 T3 DK 2379581T3 DK 10787815 T DK10787815 T DK 10787815T DK 2379581 T3 DK2379581 T3 DK 2379581T3
- Authority
- DK
- Denmark
- Prior art keywords
- multimerically
- ligands
- ability
- link
- modified ubiquitin
- Prior art date
Links
- 102000044159 Ubiquitin Human genes 0.000 title 1
- 108090000848 Ubiquitin Proteins 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/525—Tumour necrosis factor [TNF]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1041—Ribosome/Polysome display, e.g. SPERT, ARM
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/1034—Isolating an individual clone by screening libraries
- C12N15/1044—Preparation or screening of libraries displayed on scaffold proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
- G01N33/6845—Methods of identifying protein-protein interactions in protein mixtures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6878—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids in eptitope analysis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/95—Fusion polypeptide containing a motif/fusion for degradation (ubiquitin fusions, PEST sequence)
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Crystallography & Structural Chemistry (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Bioinformatics & Computational Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09179147 | 2009-12-14 | ||
| EP10162264 | 2010-05-07 | ||
| EP10186980 | 2010-10-08 | ||
| PCT/EP2010/069674 WO2011073214A2 (en) | 2009-12-14 | 2010-12-14 | A method for identifying hetero-multimeric modified ubiquitin proteins with binding capability to ligands |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2379581T3 true DK2379581T3 (da) | 2014-01-06 |
Family
ID=43648750
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK10787815.9T DK2379581T3 (da) | 2009-12-14 | 2010-12-14 | Fremgangsmåde til identifikation af hetero-multimerisk modificerede ubiquitinproteiner med evne til binding til ligander |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US8921304B2 (da) |
| EP (3) | EP2379581B1 (da) |
| JP (3) | JP5749733B2 (da) |
| KR (2) | KR101353677B1 (da) |
| CN (2) | CN102753568B (da) |
| AU (2) | AU2010332938B2 (da) |
| BR (2) | BR112012014194A2 (da) |
| CA (3) | CA2782093A1 (da) |
| DK (1) | DK2379581T3 (da) |
| ES (1) | ES2441803T3 (da) |
| IL (2) | IL219755A (da) |
| PL (1) | PL2379581T3 (da) |
| RU (2) | RU2556820C2 (da) |
| WO (3) | WO2011073214A2 (da) |
Families Citing this family (81)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| US6639684B1 (en) * | 2000-09-13 | 2003-10-28 | Nextengine, Inc. | Digitizer using intensity gradient to image features of three-dimensional objects |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| EP1925664A1 (en) | 2006-11-15 | 2008-05-28 | Scil proteins GmbH | Artificial binding proteins based on a modified alpha helical region of ubiquitin |
| BR112012014194A2 (pt) * | 2009-12-14 | 2017-01-10 | Scil Proteins Gmbh | um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos |
| EP2721152B1 (en) | 2011-06-15 | 2019-03-27 | Navigo Proteins GmbH | Dimeric binding proteins based on modified ubiquitins |
| WO2012171541A1 (en) | 2011-06-15 | 2012-12-20 | Scil Proteins Gmbh | Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins |
| WO2012172054A1 (en) * | 2011-06-16 | 2012-12-20 | Scil Proteins Gmbh | Modified multimeric ubiquitin proteins binding vegf-a |
| DK3553084T3 (da) | 2011-11-16 | 2023-02-20 | Adrenomed Ag | Anti-adrenomedullin (adm)-antistof eller anti-adm-antistoffragment eller anti-adm-non-ig-scaffold til forebyggelse eller reduktion af organdysfunktion eller organsvigt hos en patient med en kronisk eller akut sygdom eller akut tilstand |
| LT2780371T (lt) | 2011-11-16 | 2019-05-27 | Adrenomed Ag | Adrenomeduliną (adm) atpažįstantis antikūnas arba anti-adm antikūno fragmentas, arba anti-adm ne ig struktūros karkasas, skirti paciento, sergančio lėtine arba ūmia liga, skysčių pusiausvyros reguliavimui |
| JP6321545B2 (ja) | 2011-11-16 | 2018-05-09 | アドレノメト アクチェンゲゼルシャフト | 治療法における使用のための抗アドレノメデュリン（ＡＤＭ）抗体、抗ＡＤＭ抗体フラグメント又は抗ＡＤＭ非Ｉｇ足場 |
| SG11201402362VA (en) | 2011-11-16 | 2014-06-27 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for reducing the risk of mortality in a patient having a chronic or acute disease or acute condition |
| EP2780370B1 (en) | 2011-11-16 | 2019-09-25 | AdrenoMed AG | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy of an acute disease or acute condition of a patient for stabilizing the circulation |
| DK2780717T3 (da) | 2011-11-16 | 2017-02-13 | Sphingotec Gmbh | Adrenomedullinassays og fremgangsmåder til bestemmelse af modent adrenomedullin |
| CN103308689B (zh) | 2012-03-08 | 2017-04-12 | 思芬构技术有限公司 | 用于预测雌性对象中患上癌症的风险或诊断癌症的方法 |
| CN103308673B (zh) | 2012-03-08 | 2017-05-31 | 思芬构技术有限公司 | 用于预测雌性对象中发生心血管事件的风险的方法 |
| CN103308670B (zh) | 2012-03-08 | 2017-06-09 | 思芬构技术有限公司 | 用于预测对象患糖尿病和/或代谢综合征的风险的方法 |
| EP2638916A1 (en) * | 2012-03-16 | 2013-09-18 | Covagen AG | Novel binding molecules with antitumoral activity |
| MX354717B (es) * | 2012-03-16 | 2018-03-16 | Covagen Ag | Moleculas de union novedosas con actividad antitumoral. |
| EP2861616A1 (en) * | 2012-06-13 | 2015-04-22 | Scil Proteins GmbH | Human fusion proteins comprising single chain tnfalpha and targeting domains |
| CA2886779C (en) | 2012-10-02 | 2022-11-01 | Sphingotec Gmbh | A method for diagnosing or monitoring kidney function or diagnosing kidney dysfunction |
| WO2014094799A1 (en) | 2012-12-19 | 2014-06-26 | Scil-Proteins-Gmbh | Ubiquitin moieties as a means for prolonging serum half-life |
| ES2879023T3 (es) | 2013-01-08 | 2021-11-19 | Sphingotec Gmbh | Niveles en ayunas de la hormona de crecimiento como marcador predictivo de riesgo cardiovascular |
| EP2976646B1 (en) | 2013-03-20 | 2020-08-19 | sphingotec GmbH | Adrenomedullin to guide therapy of blood pressure decline |
| CN103834664B (zh) * | 2014-03-27 | 2016-05-04 | 吉林大学 | 重组表皮生长因子egf及其制备方法 |
| US10925980B2 (en) | 2014-08-04 | 2021-02-23 | Case Western Reserve University | Molecular probes and methods of use |
| EP3677285B1 (en) * | 2014-08-04 | 2023-12-13 | Case Western Reserve University | Targeting peptides for detecting prostate cancer |
| EP3002589A1 (en) | 2014-10-01 | 2016-04-06 | sphingotec GmbH | A method for stratifying a female subject for hormone replacement therapy |
| DK3253795T3 (da) | 2015-02-06 | 2019-07-29 | Navigo Proteins Gmbh | Hidtil ukendte bindende proteiner, der omfatter et ubiquitin-mutein, og antistoffer eller antistoffragmenter |
| DK3253785T3 (da) | 2015-02-06 | 2019-07-08 | Navigo Proteins Gmbh | Hidtil ukendte egfr-bindingsproteiner |
| WO2016170023A1 (en) | 2015-04-24 | 2016-10-27 | Sphingotec Gmbh | A method for predicting the risk of incidence of chronic kidney disease |
| BR112018000477A2 (pt) | 2015-07-16 | 2018-09-18 | Navigo Proteins Gmbh | proteína de ligação de imunoglobulina não natural, composição, uso da proteína de ligação de ig não natural, método de purificação de afinidade de imunoglobulinas, método de geração de uma proteína de ligação de imunoglobulina não natural, molécula de ácido nucleico, vetor, célula hospedeira ou um hospedeiro não humano, e método para a produção de uma proteína de ligação de imunoglobulina não natural |
| WO2017013136A1 (en) | 2015-07-20 | 2017-01-26 | Scil Proteins Gmbh | Novel binding proteins based on di-ubiquitin muteins and methods for generation |
| CN107849147B (zh) * | 2015-07-20 | 2021-09-17 | 纳维格蛋白质有限公司 | 基于二泛素突变蛋白的Her2结合蛋白 |
| JP6256445B2 (ja) * | 2015-09-30 | 2018-01-10 | ダイキン工業株式会社 | Ｉｃカートリッジ及環境調整装置 |
| LU92906B1 (en) | 2015-12-14 | 2017-06-20 | Luxembourg Inst Science & Tech List | Method for enzymatically modifying the tri-dimensional structure of a protein |
| EP4417218A2 (en) | 2016-04-21 | 2024-08-21 | 4TEEN4 Pharmaceuticals GmbH | Methods for determining dpp3 and therapeutic methods |
| CN105958923B (zh) * | 2016-04-22 | 2018-06-19 | 宁波大智机械科技股份有限公司 | 一种太阳能光伏板的屋顶瓦片连接结构 |
| CN109310780A (zh) | 2016-05-04 | 2019-02-05 | 纳维格蛋白质有限公司 | 包含肽接头的用于化学部分位点-特异性偶联的靶向化合物 |
| MA45493A (fr) | 2016-06-27 | 2019-05-01 | Aicuris Anti Infective Cures Gmbh | Inhibiteurs d'entrée de hcmv. |
| SG11201900133WA (en) | 2016-07-08 | 2019-02-27 | Sphingotec Gmbh | Adrenomedullin for assessing congestion in a subject with acute heart failure |
| EP4177260A1 (en) | 2016-08-11 | 2023-05-10 | Repligen Corporation | Alkaline stable fc-binding proteins for affinity chromatography |
| EP3309550A1 (en) | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| CN110167962B (zh) | 2016-12-16 | 2024-06-07 | 艾德里诺医药公司 | 用于干预和治疗需要的患者的充血的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架 |
| EP3339324A1 (en) | 2016-12-22 | 2018-06-27 | sphingotec GmbH | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in intervention and therapy of congestion in a patient in need thereof |
| CN106905435B (zh) * | 2017-03-13 | 2020-04-10 | 武汉海沙百得生物技术有限公司 | 一种制备基于蛋白a突变体的结合蛋白的方法 |
| JP7271442B2 (ja) | 2017-05-30 | 2023-05-11 | シュピーンゴテック ゲゼルシャフト ミット ベシュレンクテル ハフツング | 腎機能を診断またはモニターする方法、または腎機能障害を診断することを補助する方法 |
| US20220227854A1 (en) | 2017-09-25 | 2022-07-21 | Adrenomed Ag | Anti-adrenomedullin (adm) binder for use in therapy or prevention of symptoms of illness |
| BR112020005682A2 (pt) | 2017-10-18 | 2020-10-20 | Adrenomed Ag | monitoração de terapia sob tratamento com um aglutinante de antiadrenomedulina (adm) |
| SG11202002391PA (en) | 2017-10-24 | 2020-04-29 | Sphingotec Gmbh | Selenoprotein p for prediction of a first cardiovascular event |
| JP7424972B2 (ja) | 2017-10-25 | 2024-01-30 | ４ティーン４ ファーマシューティカルズ ゲゼルシャフト ミット ベシュレンクテル ハフツング | 特定のｄｐｐ３エピトープに指向され、そしてそれに結合するｄｐｐ３バインダー、ならびに酸化ストレスに関連する疾患／急性病態の予防または治療におけるその使用 |
| US11414466B2 (en) | 2017-11-07 | 2022-08-16 | Navigo Proteins Gmbh | Fusion proteins with specificity for ED-B and long serum half-life for diagnosis or treatment of cancer |
| MX2020008345A (es) | 2018-02-08 | 2020-09-25 | Sphingotec Gmbh | Adrenomedulina (adm) para el diagnostico y/o prediccion de demencia y un aglutinante de anti-adrenomedulina para usarse en la terapia o prevencion de demencia. |
| EP3569614A1 (en) | 2018-05-18 | 2019-11-20 | Julius-Maximilians-Universität Würzburg | Compounds and methods for the immobilization of myostatin-inhibitors on the extracellular matrix by transglutaminase |
| KR20190135393A (ko) * | 2018-05-28 | 2019-12-06 | 주식회사 원진바이오테크놀로지 | 폴리유비퀴틴 스캐폴드에 결합된 생체분자들의 선형 멀티머 중합체 및 이의 용도 |
| EP3586865A1 (en) | 2018-06-21 | 2020-01-01 | Charité - Universitätsmedizin Berlin | Complement anaphylatoxin binders and their use in treatment of a subject having an ocular wound and/or fibrosis |
| EP3898659A1 (en) * | 2018-12-18 | 2021-10-27 | Navigo Proteins Gmbh | Novel folr1 specific binding proteins for cancer diagnosis and treatment |
| CN113631926A (zh) | 2018-12-20 | 2021-11-09 | 思芬构技术有限公司 | 心力衰竭中的硒蛋白p |
| EP3897686A2 (en) | 2018-12-21 | 2021-10-27 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for a treatment with angiotensin-receptor-agonist and/or a precursor thereof |
| CN113677698A (zh) * | 2019-04-10 | 2021-11-19 | 纳维格蛋白质有限公司 | 用于癌症诊断和治疗的新的psma特异性结合蛋白 |
| BR112022001417A2 (pt) | 2019-08-15 | 2022-05-24 | Sphingotec Gmbh | Método para diagnóstico ou monitoramento de função renal ou diagnóstico de disfunção renal em pacientes pediátricos |
| CA3148275A1 (en) | 2019-08-30 | 2021-03-04 | 4TEEN4 Pharmaceuticals GmbH | Therapy guidance and/or therapy monitoring for treatment of shock |
| CN115244071A (zh) | 2019-11-27 | 2022-10-25 | 株式会社原真生物技术 | 延长生物体内持续时间的多功能多特异性多聚体生物分子聚合物 |
| EP3871689A1 (en) | 2020-02-26 | 2021-09-01 | sphingotec GmbH | Anti-adm-antibodies binding to the free n-terminus for accelerated transition of adm-gly to bio-adm in patients with adm-gly/ bio-adm ratio above a threshold and combination with vitamin c |
| CN115244401A (zh) | 2020-02-27 | 2022-10-25 | 4Teen4制药有限公司 | 用于在休克患者中进行nt-adm抗体的治疗指导、监测和分层的dpp3 |
| CN115244080A (zh) | 2020-02-27 | 2022-10-25 | 艾德里诺医药公司 | 用于治疗或预防休克的抗肾上腺髓质素(ADM)抗体或抗ADM抗体片段或抗ADM非Ig支架 |
| CN115244081A (zh) | 2020-02-27 | 2022-10-25 | 艾德里诺医药公司 | 用于治疗休克患者的抗肾上腺髓质素(adm)结合剂 |
| EP4121763A1 (en) | 2020-03-16 | 2023-01-25 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| MX2022011581A (es) | 2020-03-16 | 2022-10-18 | Adrenomed Ag | Proadrenomedulina o fragmento de la misma en pacientes infectados con coronavirus y tratamientos con aglutinante contra la adrenomedulina. |
| EP3922993A1 (en) | 2020-06-12 | 2021-12-15 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 in patients infected with coronavirus |
| EP4023218A1 (en) | 2020-12-02 | 2022-07-06 | S-Form Pharma | Combination therapy for patients having acute and/or persistent dyspnea |
| CN114854739B (zh) * | 2021-02-04 | 2024-02-06 | 中国科学院苏州纳米技术与纳米仿生研究所 | 一种细胞外基质及其制备方法和应用 |
| CN117529664A (zh) | 2021-06-18 | 2024-02-06 | 思芬构技术有限公司 | 用于预测脓毒症和脓毒性休克的方法 |
| WO2023275099A1 (en) | 2021-06-29 | 2023-01-05 | Berysol Gmbh | Composite biomarker for the identification of selenium deficiency in a bodily fluid |
| AU2023233838A1 (en) | 2022-03-15 | 2024-09-26 | Adrenomed Ag | Stable aqueous formulation of an anti-adrenomedullin (adm) antibody or anti-adm antibody fragment |
| WO2024023368A1 (en) | 2022-07-29 | 2024-02-01 | 4TEEN4 Pharmaceuticals GmbH | Prediction of an increase of dpp3 in a patient with septic shock |
| WO2024023369A1 (en) | 2022-07-29 | 2024-02-01 | Adrenomed Ag | Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for use in therapy or prevention of shock |
| WO2024088967A1 (en) * | 2022-10-24 | 2024-05-02 | Navigo Proteins Gmbh | Novel proteins with high binding affinity to programmed death ligand 1 (pd-l1) |
| WO2024126793A1 (en) | 2022-12-15 | 2024-06-20 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitor for improvement of pulmonary function in critically ill patients |
| WO2024194276A1 (en) | 2023-03-17 | 2024-09-26 | Pam Theragnostics Gmbh | Methods for determining peptidylglycine alpha-amidating monooxygenase (pam) and its use for diagnostic purpose |
| WO2024200862A1 (en) | 2023-03-29 | 2024-10-03 | 4TEEN4 Pharmaceuticals GmbH | Dpp3 inhibitor for myocardial protection and prevention of myocardial injury in critically ill patients with blood pressure decline |
Family Cites Families (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| SE9103701D0 (sv) * | 1991-12-13 | 1991-12-13 | Kabi Pharmacia Ab | Apolipoprotein |
| WO1997012992A2 (en) | 1995-10-02 | 1997-04-10 | Royal Netherlands Academy Of Arts And Sciences | Diagnosis method for a disease caused by a frameshift mutation in a gene and reagents therefore |
| CA2235223A1 (en) | 1995-10-30 | 1997-05-09 | Massachusetts Institute Of Technology | Rationally designed polysaccharide lyases derived from heparinase i |
| US5789166A (en) | 1995-12-08 | 1998-08-04 | Stratagene | Circular site-directed mutagenesis |
| GB9610967D0 (en) | 1996-05-24 | 1996-07-31 | Cambridge Antibody Tech | Specific binding members,materials and methods |
| FR2761688A1 (fr) | 1997-04-02 | 1998-10-09 | Transgene Sa | Fibre adenovirale modifiee et adenovirus cibles |
| FR2761689B1 (fr) | 1997-04-02 | 1999-06-25 | Transgene Sa | Fibre adenovirale modifiee et adenovirus cibles |
| DK0985032T4 (da) | 1997-05-28 | 2009-08-31 | Crescendo Biolog Ltd | Ribosom-komplekser som selektionspartikler til in vitro fremvisning og evolution af proteiner |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| TWI259837B (en) | 1998-05-11 | 2006-08-11 | Eidgenossische Tech Hochscule | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| US20030045681A1 (en) | 1998-05-11 | 2003-03-06 | Anthony J. Zelano | Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis |
| DE19932688B4 (de) | 1999-07-13 | 2009-10-08 | Scil Proteins Gmbh | Design von Beta-Faltblatt-Proteinen des gamma-II-kristallins antikörperähnlichen |
| ATE333900T1 (de) | 2000-02-24 | 2006-08-15 | Philogen Spa | Zusamensetzungen und verfahren zur behandlung von angiogenese in pathologischen schädigungen |
| EP1259548A1 (en) | 2000-02-24 | 2002-11-27 | Eidgenössische Technische Hochschule Zürich | Antibody specific for the ed-b domain of fibronectin, conjugates comprising said antibody, and their use for the detection and treatment of angiogenesis |
| US6799121B2 (en) | 2000-03-30 | 2004-09-28 | York University | Sequencing of peptides by mass spectrometry |
| US20110179531A1 (en) | 2000-05-09 | 2011-07-21 | Kovalic David K | Nucleic acid molecules and other molecules associated with plants and uses thereof for plant improvement |
| US20030073623A1 (en) | 2001-07-30 | 2003-04-17 | Drmanac Radoje T. | Novel nucleic acid sequences obtained from various cDNA libraries |
| US20040043386A1 (en) | 2002-08-30 | 2004-03-04 | Todd Pray | Methods and compositions for functional ubiquitin assays |
| US20100212037A1 (en) | 2002-10-16 | 2010-08-19 | Anja Katrin Bosserhoff | Mia-2 protein |
| US20040076965A1 (en) | 2002-10-16 | 2004-04-22 | Bosserhoff Anja Katrin | MIA-2 protein |
| DE10256669B4 (de) | 2002-12-04 | 2006-03-09 | Universitätsklinikum Charité an der Humboldt-Universität zu Berlin Technologietransferstelle | Gemisch mindestens zweier Fusionsproteine sowie ihre Herstellung und Verwendung |
| US7772188B2 (en) * | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| DE10324447A1 (de) | 2003-05-28 | 2004-12-30 | Scil Proteins Gmbh | Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin |
| AU2003250972A1 (en) | 2003-07-14 | 2005-01-28 | Mattex Leisure Industries | Artificial turf filament and artificial turf system |
| CA2544764A1 (en) | 2003-11-04 | 2005-05-19 | Yale University | Protein binding miniature proteins |
| WO2005059131A2 (en) | 2003-12-11 | 2005-06-30 | Yale University | Protein binding miniature proteins and uses thereof |
| DE102004049479A1 (de) | 2004-10-11 | 2006-04-13 | Scil Proteins Gmbh | Proteinkonjugate zur Verwendung in Therapie, Diagnose und Chromatographie |
| US8455625B2 (en) | 2005-05-11 | 2013-06-04 | Philogen S.P.A. | Fusion protein of antibody L19 against fibronectin ED-B and interleukin 12 |
| JP2009514540A (ja) | 2005-11-09 | 2009-04-09 | バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト | 機能−阻止抗−ｅｄ−ｂ−フィブロネクチン抗体（ｐｒｉｖａｔｅ）の同定及び特徴化 |
| EP1842553A1 (en) | 2006-04-07 | 2007-10-10 | Bayer Schering Pharma Aktiengesellschaft | Combination of an anti-EDb fibronectin domain antibody/IL2 fusion protein and a further small molecule |
| EP2016098B1 (en) | 2006-05-08 | 2016-09-07 | Philogen S.p.A. | Antibody-targeted cytokines for therapy |
| EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
| EP1925664A1 (en) | 2006-11-15 | 2008-05-28 | Scil proteins GmbH | Artificial binding proteins based on a modified alpha helical region of ubiquitin |
| EP1955712A1 (en) * | 2007-02-09 | 2008-08-13 | Scil proteins GmbH | Multimeric conjugate |
| BR112012014194A2 (pt) | 2009-12-14 | 2017-01-10 | Scil Proteins Gmbh | um método para identificar proteínas ubiquitinas modificadas hetero-multiméricas com capacidade de ligação a ligandos |
-
2010
- 2010-12-14 BR BR112012014194A patent/BR112012014194A2/pt not_active Application Discontinuation
- 2010-12-14 CA CA2782093A patent/CA2782093A1/en not_active Abandoned
- 2010-12-14 AU AU2010332938A patent/AU2010332938B2/en active Active
- 2010-12-14 AU AU2010332932A patent/AU2010332932B2/en active Active
- 2010-12-14 JP JP2012542582A patent/JP5749733B2/ja active Active
- 2010-12-14 EP EP10787815.9A patent/EP2379581B1/en active Active
- 2010-12-14 RU RU2012114662/10A patent/RU2556820C2/ru active
- 2010-12-14 PL PL10787815T patent/PL2379581T3/pl unknown
- 2010-12-14 CN CN201080056911.6A patent/CN102753568B/zh active Active
- 2010-12-14 KR KR1020117018847A patent/KR101353677B1/ko active IP Right Grant
- 2010-12-14 BR BR112012014417-0A patent/BR112012014417B1/pt active IP Right Grant
- 2010-12-14 WO PCT/EP2010/069674 patent/WO2011073214A2/en active Application Filing
- 2010-12-14 RU RU2012115491/10A patent/RU2553333C2/ru active
- 2010-12-14 JP JP2012542583A patent/JP5667207B2/ja active Active
- 2010-12-14 CN CN2010800569915A patent/CN102753569A/zh active Pending
- 2010-12-14 WO PCT/EP2010/069666 patent/WO2011073209A1/en active Application Filing
- 2010-12-14 EP EP10790970.7A patent/EP2367843B1/en active Active
- 2010-12-14 US US13/142,195 patent/US8921304B2/en active Active
- 2010-12-14 US US13/144,809 patent/US8748351B2/en active Active
- 2010-12-14 CA CA2778872A patent/CA2778872C/en active Active
- 2010-12-14 ES ES10787815.9T patent/ES2441803T3/es active Active
- 2010-12-14 WO PCT/EP2010/069665 patent/WO2011073208A1/en active Application Filing
- 2010-12-14 JP JP2012504036A patent/JP2012523227A/ja active Pending
- 2010-12-14 CA CA2778871A patent/CA2778871C/en active Active
- 2010-12-14 KR KR1020127016987A patent/KR101436222B1/ko active IP Right Grant
- 2010-12-14 DK DK10787815.9T patent/DK2379581T3/da active
- 2010-12-14 EP EP10790449.2A patent/EP2513138B1/en active Active
- 2010-12-14 US US13/516,002 patent/US20120301393A1/en not_active Abandoned
-
2012
- 2012-05-13 IL IL219755A patent/IL219755A/en active IP Right Grant
- 2012-05-13 IL IL219754A patent/IL219754A/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2379581T3 (da) | Fremgangsmåde til identifikation af hetero-multimerisk modificerede ubiquitinproteiner med evne til binding til ligander | |
| DK2723771T3 (da) | Serumalbuminbindende proteiner | |
| BR112013014278A2 (pt) | proteínas de ligação a tnf-a | |
| DK2643349T3 (da) | Designede repeat-proteiner, der binder til serumalbumin | |
| DK2784157T3 (da) | Designfremgangsmåde til et rna-bindende protein under anvendelse af ppr-motiv og anvendelse deraf | |
| DK2651249T3 (da) | Fremgangsmåde til fremstilling af en valleproteinsammensætning med reduceret astringens | |
| DK3178490T3 (da) | RSV F-proteinsammensætninger og fremgangsmåder til fremstilling af disse | |
| DK2794907T3 (da) | Fremgangsmåder og materialer til vurdering af tab af heterozygositet | |
| CO7020862A2 (es) | Proteinas de unión al antígeno cd27l | |
| BRPI0920749A2 (pt) | proteínas de ligação de antagonista multialvo cd86 | |
| DK2742135T4 (da) | Bindingsmodificerede gapped oligomeriske forbindelser og anvendelser deraf | |
| BR112012001681A2 (pt) | domínios variáveis de ligação de anti-albumina sérica aperfeiçoados | |
| DK2977455T3 (da) | Fremgangsmåde til langfragmentaflæsnings-sekventering | |
| DK2370814T3 (da) | Fremgangsmåde til diagnosticering af allergiske reaktioner | |
| DK2606061T3 (da) | Bindingsproteiner til hepcidin | |
| DK2780375T3 (da) | Bindingsmolekyler til bcma og cd3 | |
| DK3543333T3 (da) | Fremgangsmåde til screening af alfa-amylaser | |
| DK3714788T3 (da) | Fremgangsmåde til fremstilling af forbedrede analytsensorer | |
| DK2411048T3 (da) | Adjuvanterende meningokok-faktor h-bindingsprotein | |
| HK1202444A1 (en) | Il-1 binding proteins il-1 | |
| DK2513135T3 (da) | Fremgangsmåde til oprensning af polypeptider | |
| DK2531526T3 (da) | Fremgangsmåde til opnåelse af antistoffer | |
| DK2358661T3 (da) | Fremgangsmåde til fremstilling af trans-4-amino-cyclohexyl-eddikesyreethylester-hcl | |
| DK2721152T3 (da) | Dimere bindingsproteiner baseret på modificerede ubiquitiner | |
| DK2398817T4 (da) | Fremgangsmåde til rensning af lipopeptider |